Inter- and intra-observer variability in the selection of therapy for infantile hemangiomas among pediatric dermatologists in Spain.
María Colmenero SendraJavier Del BozJosé Bernabeu WittelEsther RoéMarta Feito-RodríguezMaría Asunción Vicente-VillaAna Martín-SantiagoSara Isabel Palencia PérezAntoni AzonMarta Valdivielso-RamosAntonio TorreloAna Isabel Sánchez MoyaMinia Campos-DominguezGloria Garnacho-SaucedoJosé Manuel Azaña DefezÁngel Vera CasañoJesús Tercedor-SánchezRebeca AlcaláMaría Antonia González-EnseyatAniza GiacamanÁngela Hernández-MartinMaría Teresa Monserrat GarcíaAna BauzáJavier Domínguez-CruzIgnacio García DovalMercè Grau-PerezPublished in: Pediatric dermatology (2022)
= 0.38, 95% CI: 0.27-0.48, respectively). Propranolol was the main option for high-risk hemangiomas (86.4%), timolol for intermediate-risk (36.8%), and observation for low-risk ones (55.9%). The intra-rater agreement was good. The inter-rater agreement between pediatric dermatologists on the treatment of IH is only fair. Variability was most significant with intermediate- and low-risk hemangiomas.